Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
crispr
13
×
editas medicine
13
×
life sciences
national blog main
biotech
boston blog main
boston top stories
cancer
national top stories
crispr therapeutics
national
san francisco blog main
clinical trials
deals
gene editing
new york blog main
san francisco top stories
tc
allergan
bio
biology
boston
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
health
intellia therapeutics
ipo
jennifer doudna
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
What
gene
crispr
editing
editas
medicine
read
bio
biotech
cas
ceo
roundup
berkeley’s
car
century
charpentier
colleague
doudna
emmanuelle
experimental
genetic
human
institute
jennifer
katrine
max
medicines
month
new
nobel
patent
prize
rights
science
technology
therapy
today
went
abbvie
access
acquisitions
Language
unset
Current search:
crispr
×
" editas medicine "
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@techcrunch.com
7 years ago
Oral arguments for who owns CRISPR-Cas9 starts next month
@techcrunch.com
7 years ago
CRISPR loses Nobel to tiny machines
@techcrunch.com
7 years ago
CRISPR will have to wait for that Nobel prize
@techcrunch.com
7 years ago
Reshaping human health and changing lives through gene editing
@techcrunch.com
8 years ago
Editas biotech stock drops by 26% over CRISPR patent dispute